/ 8 items

#ALKS↓

Featured/ ALKS/ 10/22/2025 · 8:05 AM

Alkermes to Acquire Avadel for Up to $2.1 Billion, Expanding Into Sleep Medicine Market

Alkermes (ALKS) announces $2.1B acquisition of Avadel Pharmaceuticals (AVDL) to gain approved narcolepsy drug Lumryz and enter the growing sleep medicine market. Deal expected Q1 2026.

ALKS/ 09/08/2025 · 7:17 AM

A New Dawn for Narcolepsy: Understanding Alixorexton's Promise

Alixorexton, a new drug for narcolepsy type 1, shows great promise. It helps patients stay awake longer (28 mins, considered normal), reduces sleepiness, cataplexy, fatigue, and improves focus. It's well-tolerated and moving to Phase 3, signaling a potential new era for treatment.